Viking Therapeutics (NASDAQ:VKTX) shows promise in the competitive GLP-1 and weight loss market, with its VK2735 drug demonstrating significant weight reduction. With positive Phase 2 results and a potential market share, VKTX stands out as an attractive investment opportunity.